Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies To Support SP-103 5.4%, A Triple Strength Formulation Of ZTlido, In Treatment Of Musculoskeletal Pain Disorders
Portfolio Pulse from Benzinga Newsdesk
Scilex Holding Company (NASDAQ:SCLX) has announced new data from skin penetration studies supporting SP-103 5.4%, a triple strength formulation of ZTlido, in the treatment of musculoskeletal pain disorders. The studies showed a higher diffusive transport of lidocaine compared to diclofenac, with SP-103 resulting in a significantly higher lidocaine concentration in muscle tissue than commercially available ZTlido. The company believes these results indicate that SP-103 is highly effective in delivering lidocaine into muscle tissue in areas of localized pain.
November 02, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scilex's new data supports the effectiveness of SP-103 in treating musculoskeletal pain disorders. This could potentially expand the product's market and increase revenues.
The new data shows that SP-103 is more effective in delivering lidocaine into muscle tissue than ZTlido. This could potentially expand the product's market beyond peripheral neuropathic pain to other types of pain, including musculoskeletal pain. This could lead to increased sales and revenues for Scilex.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100